SMS Pharmaceuticals Limited (SMSPHARMA) Financial History

Name: SMS Pharmaceuticals Limited (SMSPHARMA) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - General · DATA UPDATED 2026-09-20

SMS Pharmaceuticals Limited (SMSPHARMA) operates in the Drug Manufacturers - General industry and is headquartered in Hyderabad, India with about 1,617 employees. Its market capitalization is roughly ₹41 billion. In the fiscal year ended 2026-03-31, SMSPHARMA reported ₹8.8B in revenue and ₹1.0B in net income.

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally.

Interactive charts & full statements →

SMSPHARMA Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹8.8B	₹7.8B	₹7.1B	₹5.2B	—
Gross Profit	₹3.0B	₹2.6B	₹2.1B	₹1.3B	—
Operating Income (EBIT)	₹1.3B	₹1.0B	₹852M	₹225M	—
Net Income	₹1.0B	₹691M	₹498M	(₹71M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMSPHARMA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2024-12-31
Total Revenue	₹2.1B	₹2.4B	₹2.1B	₹2.4B	₹2.0B	—
Gross Profit	₹749M	₹813M	₹749M	₹769M	₹654M	—
Operating Income (EBIT)	₹310M	₹298M	₹336M	₹383M	₹282M	—
Net Income	₹209M	₹327M	₹235M	₹253M	₹205M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMSPHARMA Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹36M)	(₹34M)	(₹25M)	(₹25M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMSPHARMA Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹13.6B	₹11.5B	₹10.3B	₹8.8B	—
Total Liabilities	₹5.8B	₹5.1B	₹5.0B	₹4.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SMSPHARMA viewer.

Other Companies in Drug Manufacturers - General

SYMBIOTEC · SYMBIOTEC PHARMALAB LTD — ₹70 billion
SENORES · Senores Pharmaceuticals Limited — ₹65 billion
4552 · JCR Pharmaceuticals Co., Ltd. — JPY 63 billion
BAYN · Bayer Aktiengesellschaft — €47 billion
SAIPARENT · Sai Parenteral's Limited — ₹23 billion
NGLFINE · NGL Fine-Chem Limited — ₹17 billion
TTKHLTCARE · TTK Healthcare Limited — ₹15 billion
2630 · Vigonvita Life Sciences Co., Ltd. — HK$14 billion

← SMSI All “S” companies SMST →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.